Recent Deals Suggest Proteomics, Life-Science Markets May be Poised to Renew M&A Activity

Two big recent proposed deals — a bid by Danaher to buy ABI/MDS mass-spec joint venture and MDS Analytical Technologies, and Agilent's bid for Varian — could signal a trend of consolidation in the proteomics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.